Zacks Small Cap Analysis – BIXT: Carbohydrate Drug Design within the Battle Towards Viruses – Cyber Tech

OTC:BIXT

Bioxytran, Inc. (OTC:BIXT) is a clinical-stage pharmaceutical firm targeted on growing platform applied sciences utilizing carbohydrate drug design to neutralize viruses and lengthen lifespans. The corporate’s method entails analyzing Nuclear Magnetic Resonance (NMR) imaging knowledge with synthetic intelligence software program to create novel carbohydrate buildings. These buildings goal druggable proteins just like the galectin fold. The corporate’s main drug candidates have demonstrated promise in neutralizing viruses, with current peer-reviewed analysis spotlighting the invention of the galectin fold on viral spike proteins resembling these present in COVID-19, RSV, and H1N1. Bioxytran’s know-how reveals potential for addressing varied medical wants in virology, degenerative illnesses, and hypoxia. The corporate’s major candidate, Prolectin-M, goals to counter galectins concerned in inflammatory, fibrotic, and malignant circumstances. Moreover, BIXT is growing therapies for pulmonary fibrosis and stroke.

ProLectin-M and Covid-19

Bioxytran makes a speciality of formulating oral Galectin inhibitors. Galectins play roles in antiviral protection, immune responses, and irritation regulation, probably influencing the course of COVID-19. ProLectin-M is the corporate’s oral galectin antagonist that goals to dam viral entry and facilitate virus elimination. Designed initially for standard-risk COVID-19 sufferers, its broad-spectrum potential suggests functions for RSV and influenza. Current medical trials demonstrated that the drug achieved a 100% response price of unfavourable PCR exams by day seven, with an 88% response price inside 3 days. Moreover, no viral rebounds have been noticed within the handled inhabitants through the 14-day commentary interval. The corporate is making ready for a part 3 medical trial to hunt regulatory approval. The trial, involving 40 sufferers, will probably be randomized and double-blind. Kevin Mayo, a College of Minnesota Professor and Bioxytran advisor, highlighted the invention of a brand new viral binding area on spike proteins, facilitating the design of carbohydrate buildings to neutralize viruses. This discovery, using NMR imaging, represents a shift in virology in the direction of carbohydrate-based neutralization, probably revolutionizing antiviral therapies.

Hypoxia and Degenerative Ailments

Bioxytran can also be growing therapies for hypoxic circumstances, necrosis, and degenerative illnesses that carry oxygen to affected areas for stroke, wound, and mind injury. Leveraging issued patents and proprietary know-how, the corporate goals to develop medicine like BXT-25 for stroke remedy. BXT-25 is an injectable anti-necrosis drug designed for speedy use after an ischemic stroke. Administered intravenously, it transports oxygen to the mind by crossing the blood-brain barrier. The molecule is engineered to be about 5,000 instances smaller than a pink blood cell. Bioxytran’s patent portfolio features a methodology patent associated to co-polymer know-how and unique rights to FDA-approved OxySense know-how for real-time monitoring of oxygen provide to the mind. This know-how, licensed from MDX LifeSciences, allows speedy and cost-effective improvement of secure molecules addressing medical wants ensuing from hypoxia.

Shingles

On March 6, 2024, Bioxytran introduced a preprint displaying promising leads to clearing shingles lesions and lowering neuralgia inside 48-72 hours utilizing a topical galectin-3 antagonist. Whereas vaccines exist for shingles prevention, efficient antiviral therapies for treating outbreaks and ache are restricted. Additional analysis is required to discover expanded medical trials with galectin antagonists, with the objective of reworking shingles and neuralgia administration.

Funding

To make sure continuity and product improvement, Bioxytran’s administration crew stays targeted on securing extra funding by way of public or personal securities gross sales, debt financing, short-term financial institution loans, or a mix thereof. Administration is concentrating on elevating $5,300,000 to cowl present money owed and assist enterprise progress for roughly 15 months.

Conclusion

Bioxytran is positioned as an lively participant in pharmaceutical innovation, significantly in carbohydrate drug design, with aspirations to deal with a broad spectrum of medical challenges together with viral infections, degenerative illnesses, and hypoxia. The corporate’s main candidate ProLectin-M reveals promising potential in addressing COVID-19 and different bacterial infections. Moreover, ongoing developments in therapies for hypoxia and shingles recommend broader avenues for potential impacts in healthcare. Ongoing testing and medical trials are essential to completely assess the efficacy and security of those therapies. The corporate’s potential to safe extra funding stays a vital consider sustaining progress and advancing analysis and improvement initiatives.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to obtain our articles and studies emailed on to you every morning. Please go to our web site for added data on Zacks SCR. 

 Full Disclaimer HERE.